Alan J. Arville, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted by Bloomberg BNA, in “Attorneys Have Concerns with 340B Program Guidance.” The article discusses proposed changes the Health Resources and Services Administration may make to its 340B drug discount program.
Following is an excerpt:
Attorney Alan Arville, with Epstein Becker & Green PC in Washington, told Bloomberg BNA on Aug. 31 that the proposed guidance “provides needed clarification on the gray areas in the 340B program.”
But, he added, “a good deal of this guidance reflects how HRSA has already been interpreting the statute.”
As a result, Arville said, “until the guidance is final, it is going to be really difficult for 340B stakeholders to dissect what aspects of the guidance are actually a reflection of HRSA’s current interpretation of the statute that providers should already be complying with and what is truly new and proposed.”